We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Novel Medications for Opiate Detoxification - 4

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00000279
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : June 18, 2020
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Information provided by (Responsible Party):
Yale University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate novel medications for opiate detoxification.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Substance-Related Disorders Drug: Clonidine Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 0 participants
Primary Purpose: Treatment
Official Title: Novel Medications for Opiate Detoxification
Study Start Date : September 1994
Actual Primary Completion Date : August 1999
Actual Study Completion Date : August 1999

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Withdrawal severity

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000279


Locations
Layout table for location information
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Investigators
Layout table for investigator information
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:
AM J Drug & Alc. Abuse 21(4): 453-467, 1995; Neuropsychopharm 13(4): 323-333, 1995; Neuropsychopharm 14(3): 187-193, 1996; J Pharma & Experimental Therapeutics 276(3): 1128-1135, 1996.

Layout table for additonal information
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000279    
Other Study ID Numbers: NIDA-09250-4
P50DA009250 ( U.S. NIH Grant/Contract )
P50-09250-4
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: June 18, 2020
Last Verified: June 2020
Keywords provided by Yale University:
Opioid-Related Disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Substance-Related Disorders
Opioid-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Narcotic-Related Disorders
Clonidine
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
 Physiological Effects of Drugs
Antihypertensive Agents
Sympatholytics
Autonomic Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action